贝伐珠单抗联合替莫唑胺治疗老年复发胶质瘤的疗效及对认知功能和生活质量的影响  

Efficacy of Bevacizumab in Combination with Temozolomide in the Treatment of Recurrent Glioma in the Elderly and the Effects on Cognitive Function and Quality of Life

作　　者：杨煌强 魏俊怀 李坤鹏 江志贤 YANG Huangqiang;WEI Junhuai;LI Kunpeng;JIANG Zhixian(Department of Neurosurgery,Quanzhou First Hospital Affiliated to Fujian Medical University,Quanzhou,Fujian Province,362100 China)

机构地区：[1]福建医科大学附属泉州市第一医院神经外科,福建泉州362100

出　　处：《中外医疗》2023年第12期117-121,共5页China & Foreign Medical Treatment

摘　　要：目的探讨贝伐珠单抗联合替莫唑胺治疗老年复发胶质瘤的疗效及对认知功能和生活质量的影响。方法随机选取2020年4月—2021年10月福建医科大学附属泉州市第一医院神经外科收治的80例老年复发胶质瘤患者作为研究对象,用随机数表法将其分为对照组和观察组,各40例,对照组接受贝伐珠单抗治疗,观察组接受贝伐珠单抗联合替莫唑胺治疗。比较两组患者治疗疗效、认知功能、凝血功能、生活质量、不良反应等。结果观察组总有效率为85.00%,高于对照组的52.50%,差异有统计学意义(χ^(2)=9.832,P<0.05)。治疗后,观察组MMSE评分高于对照组,差异有统计学意义(P<0.05)。治疗后,观察组PLT低于对照组,APTT、PT、TT高于对照组,差异有统计学意义(P<0.05)。治疗后,观察组SF-36评分高于对照组,差异有统计学意义(P<0.05)。治疗后,观察组NIHSS评分、脑水肿低于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率为10.00%,低于对照组的12.50%,但差异无统计学意义(χ^(2)=0.000,P>0.05)。结论老年复发胶质瘤患者在接受贝伐珠单抗治疗基础上,再给予替莫唑胺,可更好地改善其认知功能、凝血功能、生活质量,安全且高效。Objective To investigate the efficacy of Bevacizumab combined with Temozolomide in the treatment of recurrent glioma in the elderly and the effects on cognitive function and quality of life.Methods Eighty cases of elderly patients with recurrent glioma admitted to the Department of Neurosurgery of Quanzhou First Hospital Affiliated to Fujian Medical University from April 2020 to October 2021 were randomly selected as study subjects,and they were divided into control group and observation group using random number table method,40 cases each.The control group was treated with Bevacizumab and the observation group was treated with Bevacizumab combined with Temozolomide.The treatment efficacy,cognitive function,coagulation function,quality of life,and adverse effects were compared between the two groups.Results The total effective rate of the observation group was 85.00%,which was higher than 52.50%of the control group,the difference was statistically significant(χ^(2)=9.832,P<0.05).After treatment,the MMSE score in the observation group was higher than that in the control group,the difference was statistically significant(P<0.05).After treatment,PIt in the observation group was lower than that in the control group,APTT,PT,and TT were higher than those in the control group,the difference was statistically significant(P<0.05).After treatment,the SF-36 score in the observation group was higher than that in the control group,the difference was statistically significant(P<0.05).After treatment,NIHSS score and cerebral edema in the observation group were lower than those in the control group,the difference was statistically significant(P<0.05).The incidence of adverse reactions in the observation group(10.00%)was lower than that in the control group(12.50%),the difference was not statistically significant(χ^(2)=0.000,P>0.05).Conclusion Older patients with recurrent glioma treated with Bevacizumab followed by Temozolomide can better improve their cognitive function,coagulation function,and quality of life in a safe and e

关 键 词：胶质瘤 复发 老年 认知功能 生活质量 贝伐珠单抗 替莫唑胺 

分 类 号：R5[医药卫生—内科学]